To access this element change to forms mode OFF
Grant Award View - GA289081
Interfant-21: A new international clinical trial for infants diagnosed...
GA ID:
GA289081
Agency:
Department of Health and Aged Care
Approval Date:
9-Dec-2022
Publish Date:
20-Mar-2023
Category:
Medical Research
Grant Term:
1-Feb-2023 to 31-Jan-2028
Value (AUD):
$718,933.55
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 22/23 1.1 Health Policy Research and Analysis
Grant Program:
Medical Research Future Fund
Grant Activity:
Interfant-21: A new international clinical trial for infants diagnosed with KMT2A-rearranged acute lymphoblastic leukaemia
Purpose:
Infants diagnosed with acute lymphoblastic leukaemia (ALL) have poor outcomes. Rearrangements of the KMT2A gene are present in up to 80% of infants with ALL and have exceptionally low survival rates of less than 40%. Interfant-21 is an international clinical trial that will test whether the addition of a novel immunotherapeutic agent, blinatumomab, to standard chemotherapy can improve survival in infants diagnosed with KMT2A-rearranged ALL.
GO ID:
GO Title:
MRFF 2021 Clinical Trials Activity Grant Opportunity
Internal Reference ID:
2022/MRF2023138
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Monash University
Recipient ABN:
12 377 614 012
Grant Recipient Location
Suburb:
Clayton
Town/City:
Clayton
Postcode:
3800
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC, SA, WA, QLD, Overseas
Postcode:
Multiple
Country:
AUSTRALIA, NETHERLANDS